Abstract:Abstract Background Bladder cancer (BLCA) is one of the most common malignancies worldwide. One of the main reasons for the unsatisfactory management of BLCA is the complex molecular biological mechanism. Annexin A1 (ANXA1), a Ca 2+ -regulated phospholipid-binding protein, has been demonstrated to be implicated in the progression and prognosis of many cancers. However, the expression pattern, biological function and mechanism of ANXA1 in BLCA remain unclear. Methods The clinical relevance of ANXA1 in BLCA was investigated by bioinformatics analysis based on TCGA and GEO datasets. Immunohistochemical (IHC) analysis was performed to detect the expression of ANXA1 in BLCA tissues, and the relationships between ANXA1 and clinical parameters were analyzed. In vitro and in vivo experiments were conducted to study the biological functions of ANXA1 in BLCA. Finally, the potential mechanism of ANXA1 in BLCA was explored by bioinformatics analysis and verified by in vitro and in vivo experiments. Results Bioinformatics and IHC analyses indicated that a high expression level of ANXA1 was strongly associated with the progression and poor prognosis of patients with BLCA. Functional studies demonstrated that ANXA1 silencing inhibited the proliferation, migration, invasion and epithelial–mesenchymal transition (EMT) of BLCA cells in vitro, and suppressed the growth of xenografted bladder tumors in vivo. Mechanistically, loss of ANXA1 decreased the expression and phosphorylation level of EGFR and the activation of downstream signaling pathways. In addition, knockdown of ANXA1 accelerated ubiquitination and degradation of P-EGFR to downregulate the activation of EGFR signaling. Conclusions These findings indicate that ANXA1 is a reliable clinical predictor for the prognosis of BLCA and promotes proliferation and migration by activating EGFR signaling in BLCA. Therefore, ANXA1 may be a promising biomarker for the prognosis of patients with BLCA, thus shedding light on precise and personalized therapy for BLCA in the future.

Advances in cancer treatment: a new therapeutic target, Annexin A2

Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers

Annexin I and Tumor

An overview of the regulatory role of annexin A1 in the tumor microenvironment and its prospective clinical application (Review)

Annexin A2 in Tumors of the Gastrointestinal Tract, Liver, and Pancreas

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

Annexin A1 in inflammation and breast cancer: a new axis in the tumor microenvironment

Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

Annexin A3, a Calcium-Dependent Phospholipid-Binding Protein: Implication in Cancer

Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma

Prognostic and Diagnostic Significance of Annexin A2 in Colorectal Cancer.

A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo

Anti-cancer activity of Annexin V in murine melanoma model by suppressing tumor angiogenesis.

Clinicopathological Value and Underlying Molecular Mechanism of Annexin A2 in 992 Cases of Thyroid Carcinoma

Cracking the code of Annexin A1-mediated chemoresistance

Annexin A1 in Malignant Tumors: Current Opinions and Controversies.

Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer.

Annexin A4 and cancer

Inhibition of the membrane repair protein annexin-A2 prevents tumor invasion and metastasis

Effect of Annexin A2 on Prognosis and Sensitivity to Immune Checkpoint Plus Tyrosine Kinase Inhibition in Metastatic Renal Cell Carcinoma

Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway